Clinical implications of iNOS levels in triple- negative breast cancer responding to neoadjuvant chemotherapy

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Jin, Zining ^a   Wang, Wenqian ^a   Jiang, Nan ^a   Zhang, Lei ^a   Li, Yiming ^a   Xu, Xiaoyin ^a   Cai, Shouliang ^a   Wei, Liang ^a   Liu, Xuhong ^a   Chen, Guanglei ^a   Zhou, Yizhen ^a   Liu, Cheng ^a   Li, Zhan ^a   Jin, Feng ^a   Chen, Bo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; NITRIC OXIDE; NOS2 PROTEIN, HUMAN;

ARTICLE; CANCER ADJUVANT THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CORE NEEDLE BIOPSY; MORPHOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84941309550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130286     Document Type: Article

References (26)

1. Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, et al. (2014) Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer 14: 847. doi:10.1186/1471-2407-14-847PMID: 25410881.
2. Kilburn LS, TNT Trial Management Group (2008) 'Triple negative' breast cancer: A new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 20: 35-39.
3. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819. PMID: 15510162.
4. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899-23903. PMID: 10843985.
5. Moynahan ME, Cui TY, Jasin M (2001) Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1mutation. Cancer Res 61: 4842-4850. PMID: 11406561.
6. Yadav BS, Sharma SC, Chanana P, Jhamb S (2014) Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 5:125-133. doi:10.5306/wjco.v5.i2.125 PMID: 24829859.
7. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, et al. (2011) Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16:1675-1683doi:10.1634/theoncologist.2011-0196 PMID: 22147002.
8. Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C, et al. (2012) Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat 131:437-444. doi:10.1007/s10549-011-1422-5 PMID: 21360074.
9. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. (2010) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study. Cancer 117:1819-1826doi:10.1002/cncr.25682 PMID: 21509759.
10. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, et al. (2011) Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16:1675-1683. doi:10.1634/theoncologist.2011-0196 PMID: 22147002.
11. Lechner M, Lirk P, Rieder J (2005) Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 15:277-289. PMID: 15914026.
12. Mocellin S, Bronte V, Nitti D (2007) Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 27:317-352. PMID: 16991100.
13. Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, et al. (2011) Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 32:644-651. doi:10.1016/j.tips.2011.07.001 PMID: 21893353.
14. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. (2010) Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120: 3843-3854. doi:10.1172/JCI42059 PMID: 20978357.
15. Pance A (2006) Nitric oxide and hormones in breast cancer: Allies or enemies? Future Oncol 2:275- 288. PMID: 16563095.
16. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, et al. (1998) Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58:334-341. PMID: 9443414.
17. Ray GN, Shahid M, Husain SA (2001) Effect of nitric oxide and malondialdehyde on sister-chromatid exchanges in breast cancer. Br J Biomed Sci 58:169-176. PMID: 11575740.
18. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y (2000) Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6:2408-2416. PMID: 10873093.
19. Belotte J, Fletcher NM, Awonuga AO, Alexis M, Abu-Soud HM, Saed MG, et al. (2014) The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod Sci. 21:503-508. doi:10.1177/1933719113503403 PMID: 24077440.
20. Tang CH, Grimm EA (2004) Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279:288-298. PMID: 14576150.
21. Godoy LC, Anderson CT, Chowdhury R, Trudel LJ, Wogan GN (2012) Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci USA 109:20373-20378. doi:10.1073/pnas.1218938109 PMID: 23185001.
22. Rakha EA, EI-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32. PMID: 17146782.
23. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434. PMID: 17671126.
24. Smith IE, Talbot DC (1992) Cisplatin and its analogues in the treatment of advanced breast cancer: A review. Br J Cancer 65: 787-793. PMID: 1616849.
25. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108-112. PMID: 6685001.
26. Sledge GW Jr, Loehrer PJ S, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811-1814. PMID: 3199166.